ClinicalTrials.gg

Program

E-3810

Also written as “E3810”, “Lucitanib” and “AL3810”.

Its studies are mostly in Thymoma · Genital Neoplasms, Female · Breast Neoplasms · Small Cell Lung Carcinoma · Carcinoma, Non-Small-Cell Lung, led by 3 companies.

Furthest: phase 3, since Sep 12, 200511 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eisai40 open or runningphase 3since Sep 12, 2005Sep 12, 2005none ahead
Haihe Biopharma40 open or runningphase 3since Jan 16, 2020Dec 16, 2016none ahead
Clovis Oncology30 open or runningphase 2since Apr 7, 2014Apr 7, 2014none ahead

Also a collaborator on its studies: Bristol-Myers Squibb.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 12, 2005First study: phase 3 study in Non-erosive Gastroesophageal Reflux DiseaseNew to EisaiEisai · NCT00165646 · 288 enrolled · Japan
  2. Oct 9, 2008Phase 3 study in Esophagitis, PepticEisai · NCT00770913 · 337 enrolled · Japan
  3. Jun 28, 2010Phase 1 study in HealthyEisai · NCT01153659 · 90 enrolled · United States
  4. Jul 18, 2011Phase 3 study in Stomach UlcerEisai · NCT01397448 · 472 enrolled · Japan
  5. Apr 7, 2014Clovis Oncology's first study: phase 2 study in Carcinoma, Non-Small-Cell LungNew to Clovis OncologyClovis Oncology · NCT02109016 · 18 enrolled · United States, France, Germany and more
  6. Jul 25, 2014Phase 2 study in Breast NeoplasmsClovis Oncology · NCT02202746 · 178 enrolled · United States
  7. Dec 16, 2016Haihe Biopharma's first study: phase 1 study in Advanced Solid TumorsNew to Haihe BiopharmaHaihe Biopharma · NCT03117101 · 17 enrolled · China
  8. Jul 20, 2017Phase 1 study in Colorectal NeoplasmsHaihe Biopharma · NCT03260179 · 60 enrolled · China
  9. Jul 19, 2019Phase 2 study in Genital Neoplasms, FemaleClovis Oncology · NCT04042116 · 227 enrolled · United States, Austria, Belgium and more
  10. Jan 16, 2020Phase 3 study in Small Cell Lung CarcinomaHaihe Biopharma · NCT04254471 · 313 enrolled · China
  11. Sep 11, 2026Phase 2 study in ThymomaHaihe Biopharma · NCT07824505 · 74 enrolled · China

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 11 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07824505Thymoma · China2CompletedHaihe BiopharmaSep 6, 202174
NCT04254471Small Cell Lung Carcinoma · China3UNKNOWNHaihe BiopharmaMay 22, 2022313
NCT04042116Genital Neoplasms, Female · United States, Austria, Belgium and more2SuspendedClovis OncologyJul 2023227
NCT03260179Colorectal Neoplasms · China1UNKNOWNHaihe BiopharmaJan 31, 201960
NCT03117101Advanced Solid Tumors · China1CompletedHaihe BiopharmaSep 201617
NCT02202746Breast Neoplasms · United States2TerminatedClovis OncologyJan 17, 2017178
NCT02109016Carcinoma, Non-Small-Cell Lung · United States, France, Germany and more2TerminatedClovis OncologyApr 1, 201618
NCT01397448Stomach Ulcer · Japan3CompletedEisaiMar 2013472
NCT01153659Healthy · United States1CompletedEisaiAug 201090
NCT00770913Esophagitis, Peptic · Japan3CompletedEisaiNov 2009337
NCT00165646Non-erosive Gastroesophageal Reflux Disease · Japan3CompletedEisaiOct 2005288

How it is read

Names in the registry

  • “E3810”, 8 entries
  • “Lucitanib”, 6 entries
  • “AL3810”, 4 entries
  • “lucitanib 15 mg QD”, 1 entry
  • “lucitanib 10 mg QD”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.